GlassScriptPhysician profile
Melissa Marie Etchison
NPI 1518425727
$2,211.96
in general payments reported to CMS, 2019-2025
15 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.38 · 2022: $453 · 2023: $953 · 2024: $602 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662 · Education: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.47 |
| Education | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $547.18 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Alkermes, INC. | $291.73 | 2022-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.26 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $208.11 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $207.02 | 2021-2023 | Ingrezza |
| Abbvie INC. | $202.55 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $144.19 | 2022-2023 | Invega Sustenna |
| Lundbeck LLC | $96.21 | 2021-2024 | Rexulti |
| Indivior INC. | $64.93 | 2022-2024 | Perseris |
| Pulmonx Corporation | $52.89 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $37.57 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $35.11 | 2023-2024 | Auvelity |
| Pfizer INC. | $30.51 | 2024 | |
| Owp Pharmaceuticals, INC. | $22.68 | 2024 | Subvenite |
| Corium, LLC | $20.02 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Etchison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.